| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Ropivacaine hydrochloride is a potent inhibitor of K2P and asodium channelblockerused as ananaesthetic agent, blocking neuropathic pain. It is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cells membrane.
| ln Vivo |
Ropivacaine hydrochloride, when administered epidurally, can greatly postpone the onset of neuropathic pain resulting from peripheral nerve injury and effectively block neuropathic pain (mechanical allodynia and thermal hyperalgesia) without causing analgesic tolerance[1]. Without altering pulmonary artery pressure (Ppa), pulmonary capillary pressure (Ppc), or zone characteristics (ZC), ropivacaine hydrochloride suppresses the pressure-induced rise in filtration coefficient (Kf) [2]. Pressure-induced pulmonary edema and associated hyperpermeability are avoided by ropivacaine hydrochloride by keeping lung wet-to-dry ratio, plasma volume, and PaO2 at levels comparable to those of sham-operated rats [2]. As demonstrated by a lower lung nitrotyrosine level, ropivacaine hydrochloride reduces stress-induced NO generation in comparison to hypertensive lung [2].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Adult SD (SD (Sprague-Dawley)) rat (300–400g) [2]
Doses: 1 μM Route of Administration: Infusion (added to perfusate reservoir) Experimental Results: Attenuated pressure-dependent increase in filtration coefficient (Kf) . |
| References |
|
| Additional Infomation |
Ropivacaine Hydrochloride is the hydrochloride salt of ropivacaine, a local anesthetic of the amide type with analgesic activity. Ropivacaine binds to voltage-gated sodium ion channels in the neuronal membrane, thereby preventing the permeability of sodium ions and resulting in a stabilization of the neuronal membrane and inhibition of depolarization; nerve impulse generation and propagation are blocked, resulting in a reversible loss of sensation.
An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons. |
| Molecular Formula |
C17H27CLN2O
|
|---|---|
| Molecular Weight |
310.8621
|
| Exact Mass |
310.181
|
| CAS # |
98717-15-8
|
| Related CAS # |
Ropivacaine;84057-95-4;Ropivacaine hydrochloride monohydrate;132112-35-7;Ropivacaine-d7 hydrochloride;1217667-10-1;Ropivacaine mesylate;854056-07-8;Ropivacaine-d7;684647-62-9;(Rac)-Ropivacaine-d7;1392208-04-6
|
| PubChem CID |
175804
|
| Appearance |
White to off-white solid powder
|
| Density |
1.044 g/cm3
|
| Boiling Point |
410.2ºC at 760 mmHg
|
| Flash Point |
201.9ºC
|
| LogP |
4.319
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
308
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C.Cl
|
| InChi Key |
NDNSIBYYUOEUSV-RSAXXLAASA-N
|
| InChi Code |
InChI=1S/C17H26N2O.ClH/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3;/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20);1H/t15-;/m0./s1
|
| Chemical Name |
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~32.17 mM)
H2O : ~10 mg/mL (~32.17 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2169 mL | 16.0844 mL | 32.1688 mL | |
| 5 mM | 0.6434 mL | 3.2169 mL | 6.4338 mL | |
| 10 mM | 0.3217 mL | 1.6084 mL | 3.2169 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
